Published in Oral Oncol on June 02, 2012
Treatment of older patients with head and neck cancer: a review. Oncologist (2013) 0.89
Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy. Radiother Oncol (2016) 0.77
IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80. Strahlenther Onkol (2016) 0.75
Follow-up in Head and Neck Cancer: Do More Does It Mean Do Better? A Systematic Review and Our Proposal Based on Our Experience. Clin Exp Otorhinolaryngol (2016) 0.75
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. Oncotarget (2017) 0.75
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer (2005) 2.19
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol (2012) 1.55
Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer (2006) 1.47
False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol (2004) 1.46
Nonsurgical conservative approach for laryngeal cancer: what information should patients be given? J Clin Oncol (2013) 1.40
A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol (2004) 1.35
Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest (2010) 1.30
Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol (2010) 1.01
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. Int J Radiat Oncol Biol Phys (2006) 1.00
Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res (2002) 1.00
Intensity-modulated and hypofractionated simultaneous integrated boost adjuvant breast radiation employing statics ports of tomotherapy (TomoDirect): a prospective phase II trial. J Cancer Res Clin Oncol (2013) 0.98
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res (2013) 0.96
Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol (2005) 0.96
Intensity-modulated adjuvant whole breast radiation delivered with static angle tomotherapy (TomoDirect): a prospective case series. J Cancer Res Clin Oncol (2013) 0.96
TomoDirect: an efficient means to deliver radiation at static angles with tomotherapy. Tumori (2011) 0.95
Present status and perspectives in the treatment of hormone-refractory prostate cancer. Oncology (2005) 0.92
Role of gemcitabine in metastatic breast cancer patients: a short review. Breast (2007) 0.92
Functional analysis of mutations in the putative binding site for cystic fibrosis transmembrane conductance regulator potentiators. Interaction between activation and inhibition. J Biol Chem (2007) 0.90
Five-year results of a prospective case series of accelerated hypofractionated whole breast radiation with concomitant boost to the surgical bed after conserving surgery for early breast cancer. Med Oncol (2013) 0.89
Combined chemoradiation for head and neck region myxofibrosarcoma of the maxillary sinus. Tumori (2013) 0.88
EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy. Anticancer Res (2010) 0.86
COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness. J Pathol (2009) 0.85
Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score. Support Care Cancer (2011) 0.84
Paraneoplastic brainstem encephalitis in a patient with malignant fibrous histiocytoma and atypical anti-neuronal antibodies. J Neurol (2004) 0.83
Management of 'in-field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy. Oncology (2013) 0.83
The effects on pain and activity of daily living caused by crusted exudation in patients with head and neck cancer treated with cetuximab and radiotherapy. Support Care Cancer (2011) 0.83
Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. Cancer Biol Ther (2009) 0.83
Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: a pharmacology-guided schedule. Int J Radiat Oncol Biol Phys (2006) 0.83
The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma. Oncology (2010) 0.82
Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells. Anticancer Drugs (2013) 0.82
MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens. Int J Biol Markers (2015) 0.82
Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother Pharmacol (2005) 0.82
Bilateral breast radiation delivered with static angle tomotherapy (TomoDirect): clinical feasibility and dosimetric results of a single patient. Tumori (2015) 0.81
Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer. Int J Oncol (2010) 0.80
Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications. Leuk Lymphoma (2012) 0.80
Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin Breast Cancer (2007) 0.80
Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors. Anticancer Drugs (2006) 0.79
Ultrathin hydrocolloid dressing in skin damaged from alternating radiotherapy and chemotherapy plus cetuximab in advanced head and neck cancer (G.O.N.O. AlteRCC Italian Trial): in regard to Macmillan et al. (Int J Radiat Oncol Biol Phys 2007;68:864-872). Int J Radiat Oncol Biol Phys (2007) 0.79
Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series. Cancer Invest (2015) 0.79
Endocrine modulation, inhibition of ovarian development and hepatic alterations in rainbow trout exposed to polluted river water. Environ Pollut (2010) 0.79
Comet and micronucleus assays in zebra mussel cells for genotoxicity assessment of surface drinking water treated with three different disinfectants. Sci Total Environ (2004) 0.79
Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes. Int J Clin Oncol (2012) 0.79
Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis. Cardiovasc Toxicol (2012) 0.79
Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma. Int J Biol Markers (2013) 0.79
Hypofractionation and concomitant boost to deliver adjuvant whole-breast radiation in ductal carcinoma in situ (DCIS): a subgroup analysis of a prospective case series. Med Oncol (2014) 0.79
Role of IL-8 induced angiogenesis in uveal melanoma. Invest New Drugs (2013) 0.78
Palliative radiotherapy for painful bone metastases from solid tumors delivered with static ports of tomotherapy (TomoDirect): feasibility and clinical results. Cancer Invest (2014) 0.78
Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line. Urol Oncol (2011) 0.78
Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study. Lung Cancer (2005) 0.78
Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial. Radiother Oncol (2004) 0.78
Impact of erythropoietin on the effects of irradiation under hypoxia. J Cancer Res Clin Oncol (2009) 0.78
Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients. Curr Drug Metab (2011) 0.77
Empathy in the doctor-patient relationship. J Clin Oncol (2004) 0.77
Postoperative therapy in head and neck cancer: state of the art, risk subset, prognosis and unsolved questions. Oncology (2011) 0.77
Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study. Invest New Drugs (2012) 0.77
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. Oral Oncol (2012) 0.76
Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. Cancer Treat Rev (2006) 0.76
The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines. Invest New Drugs (2015) 0.76
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines. Invest New Drugs (2015) 0.76
Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. Support Care Cancer (2014) 0.75
Stage I non-small cell lung cancer: the presence of the lymphocyte-specific protein tyrosin kinase in the tumour infiltrate is associated with a better long-term prognosis. Interact Cardiovasc Thorac Surg (2012) 0.75
Radiotherapy in pleural malignant mesothelioma: why not! In regard to Scorsetti et al. (Int J Radiat Oncol Biol Phys 2010;77:942-949); Krayenbuehl et al. (Int J Radiat Oncol Biol Phys 2010;78:628-634). Int J Radiat Oncol Biol Phys (2011) 0.75
Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion. Medicine (Baltimore) (2016) 0.75
Tracheal metastasis. J Craniofac Surg (2015) 0.75
Validation of a reverse transcription-polymerase chain reaction-based five-gene signature in non-small cell lung cancer. J Thorac Oncol (2009) 0.75
A new approach for the pixel map sensitivity (PMS) evaluation of an electronic portal imaging device (EPID). J Appl Clin Med Phys (2013) 0.75
Carboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy. Anticancer Res (2005) 0.75
Cetuximab-related radiation dermatitis in head-and-neck cancer patients: in regard to Studer et al. (Int J Radiat Oncol Biol Phys in press). Int J Radiat Oncol Biol Phys (2011) 0.75
Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: a retrospective cohort analysis. J Chemother (2013) 0.75
Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines. Urol Oncol (2012) 0.75
Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study. Anticancer Drugs (2016) 0.75
A phase II study of epirubicin, vinorelbine and cisplatin in advanced breast cancer. Anticancer Drugs (2004) 0.75
A PNA-mediated clamping PCR for routine detection of KRAS mutations in colorectal carcinoma. Int J Biol Markers (2014) 0.75
Management of oropharyngeal mycosis in head and neck cancer occurring during (chemo) radiotherapy: an Italian radio-oncologist survey. Tumori (2015) 0.75